The only antimicrobial peptide your body makes — controlled by vitamin D, tested in two wound trials, and carrying a cancer paradox that changes everything about how you should think about immune defense

Every living organism faces the same fundamental challenge: how to defend itself against microbial invasion without destroying its own tissues in the process. Humans solved this problem partly through cathelicidins — a family of antimicrobial peptides expressed across virtually all mammalian species. LL-37 is the only cathelicidin humans produce, and it is arguably the most versatile innate immune molecule in the human body: a 37-amino-acid peptide that kills bacteria, neutralizes viruses, disrupts fungal membranes, recruits immune cells to infection sites, promotes wound healing, and modulates the inflammatory response.

What makes LL-37 uniquely relevant to immune health — and what the existing Cluster B article on this compound underemphasizes — is the vitamin D connection. The human CAMP gene that encodes LL-37 contains a vitamin D response element in its promoter region. Active vitamin D (1,25-dihydroxyvitamin D3) directly upregulates LL-37 expression. This is why vitamin D deficiency correlates with increased susceptibility to infections: when your vitamin D drops, your LL-37 production drops with it, and your first-line antimicrobial defense weakens. The vitamin D–LL-37 axis is one of the best-characterized molecular links between a common nutrient deficiency and immune vulnerability.

The challenge with LL-37 as a therapeutic compound is the gap between its endogenous role and exogenous administration. Your body produces LL-37 at precise concentrations in specific tissues. The two published clinical trials tested topical application to chronic wounds — not systemic injection. The community practice of injecting LL-37 subcutaneously for immune support has zero clinical trial backing. And the cancer paradox — LL-37 promotes tumor growth in several cancer types at concentrations that overlap with therapeutic dosing — makes this compound one where the gap between fascinating biology and safe therapeutic use is wider than most people realize.

Quick Facts: LL-37 at a Glance

What Is Ll-37?

Pronunciation: ell-ell thirty-seven

You are colonized by approximately 38 trillion bacteria right now — on your skin, in your gut, in your respiratory tract. Most are harmless or beneficial. But at every mucosal surface, your body maintains a chemical defense perimeter against the ones that are not. LL-37 is the centerpiece of that perimeter: the only antimicrobial peptide in the cathelicidin family that humans express, and one of the most versatile innate immune molecules ever characterized.

The name is straightforward: LL-37 is 37 amino acids long, and it begins with two leucine residues (L-L). It is cleaved from a larger precursor protein called hCAP18 (18 kDa human cationic antimicrobial protein) by the enzyme proteinase 3, primarily inside neutrophils — the white blood cells that arrive first at any infection site. When neutrophils degranulate at a wound or infection, they release LL-37 along with a cocktail of other antimicrobial molecules, creating a chemical killing zone.

But LL-37 is not just a neutrophil weapon. It is expressed in epithelial cells across the skin, respiratory tract, urogenital tract, and gastrointestinal tract — every surface where your body meets the outside world. It is produced by macrophages, mast cells, and natural killer cells. And uniquely among antimicrobial peptides, its production is directly controlled by vitamin D: the active form of vitamin D (1,25-dihydroxyvitamin D3) binds to a vitamin D response element in the CAMP gene promoter and upregulates LL-37 transcription. This molecular link between vitamin D status and innate immune defense is one of the most important discoveries in modern immunology.

Origins and Discovery

The cathelicidin family was identified in the early 1990s through work on antimicrobial peptides stored in neutrophil granules. The human member — originally designated FALL-39 (later corrected to LL-37 after sequencing refinements) — was characterized by Gudmundsson et al. in 1996. The realization that humans expressed only a single cathelicidin, compared to dozens in other species, focused intense research attention on LL-37's multifunctionality.

The vitamin D connection was established in 2006 by Liu et al. in a landmark Science paper demonstrating that TLR activation of macrophages led to upregulation of the vitamin D receptor and the 1-alpha-hydroxylase enzyme, which in turn induced LL-37 expression. This study provided the first molecular mechanism explaining why vitamin D supplementation reduced infection risk — a connection that had been observed epidemiologically for over a century (the use of sunlight and cod liver oil for tuberculosis treatment predates the discovery of vitamin D itself).

The dual nature of LL-37 — antimicrobial defender and potential tumor promoter — was characterized over the following decade, with multiple groups demonstrating concentration- and tissue-dependent effects on cancer cell growth. This duality transformed LL-37 from a straightforward "good" immune molecule into one of the most pharmacologically complex peptides in the human body.

Mechanism of Action

LL-37 operates through at least four distinct biological mechanisms, each relevant to immune health:

Direct Antimicrobial Activity — The First Line

LL-37 is a cationic (positively charged) alpha-helical peptide that kills microbes through electrostatic disruption of their membranes. Bacterial and fungal cell membranes are negatively charged (due to lipopolysaccharide in gram-negatives, lipoteichoic acid in gram-positives, and ergosterol in fungi), while human cell membranes are relatively neutral. LL-37 exploits this charge difference: it binds to negatively charged microbial membranes, inserts its alpha-helical structure, and creates pores that destroy membrane integrity. The microbe dies by losing control of its internal environment.

The antimicrobial spectrum is remarkably broad. LL-37 is effective against gram-positive bacteria (including MRSA — PMID: PMC 8532939), gram-negative bacteria, enveloped viruses (RSV — PMID 26732674; influenza A — PMID 23052388), and fungi including the emerging pathogen Candida auris (PMID 35205958). It also shows synergy with conventional antibiotics: 70% synergy with fluconazole, 100% synergy with amphotericin B and caspofungin (PMID 35205958).

Immunomodulation — The Signaling Role

Beyond direct killing, LL-37 functions as an immune signaling molecule. It acts as a chemoattractant for neutrophils, monocytes, and T-cells — recruiting additional immune cells to infection sites. It modulates Toll-like receptor (TLR) signaling, shaping the inflammatory response. It promotes dendritic cell differentiation, bridging innate and adaptive immunity. And it neutralizes lipopolysaccharide (LPS), the bacterial endotoxin that triggers septic shock — LL-37 binds LPS and prevents it from activating the inflammatory cascade.

This immunomodulatory role means LL-37 does not simply kill pathogens — it orchestrates the immune response to pathogens. It recruits reinforcements, shapes the type of immune response that develops, and prevents the inflammation from spiraling out of control.

Wound Healing — A Downstream Consequence of Immune Defense

The wound-healing activity of LL-37 — the primary focus of the existing clinical trials — is mechanistically linked to its immune function. Wound healing requires angiogenesis (new blood vessel formation), which LL-37 promotes through FPRL1 (formyl peptide receptor-like 1). It requires epithelial migration and proliferation, which LL-37 drives through EGFR transactivation. And it requires infection control, which LL-37 provides through its direct antimicrobial activity.

In the immune health frame, wound healing is not a separate function — it is what happens when LL-37's immune defense activity is applied to damaged tissue. The same peptide that kills bacteria at a wound also recruits the cells that repair the damage and builds the blood vessels that supply the healing tissue.

The Cancer Paradox — Concentration-Dependent Dual Role

LL-37's effects on cancer are the most pharmacologically complex aspect of the compound. At approximately 5 μg/mL — a concentration achievable through exogenous administration — LL-37 acts as a growth factor for ovarian, lung, breast, and prostate cancers, malignant melanoma, and skin squamous cell carcinoma. The mechanism in ovarian cancer involves recruitment of multipotent mesenchymal stromal cells into the tumor stroma (PMID 19234121), enhancing tumor angiogenesis and promoting cancer cell proliferation.

At higher concentrations, LL-37 demonstrates anti-tumorigenic effects in colon cancer, gastric cancer, hematologic malignancies, and oral squamous cell carcinoma (PMID 26395996). In pancreatic cancer, LL-37 inhibits tumor growth by suppressing autophagy and reprogramming the tumor immune microenvironment (PMC: 9355328).

This duality is not a minor caveat — it is a central pharmacological feature. The same peptide that defends against infection can promote tumor growth, depending on the tissue and the dose. Any discussion of exogenous LL-37 administration must grapple with this paradox.

Key Research Areas and Studies

The Vitamin D–LL-37 Axis — The Immune Health Foundation

The discovery that vitamin D directly regulates LL-37 expression is arguably the most important finding for immune health. The CAMP gene contains a vitamin D response element (VDRE) in its promoter region, and active vitamin D (1,25(OH)₂D₃) binds this element to upregulate transcription. Liu et al.'s 2006 Science paper demonstrated the complete signaling chain: TLR activation → vitamin D receptor upregulation → 1-alpha-hydroxylase induction → local vitamin D activation → LL-37 expression. This means your innate immune system's antimicrobial defense is directly coupled to your vitamin D status.

The clinical implications are substantial. Vitamin D deficiency (serum 25(OH)D < 20 ng/mL) affects an estimated 1 billion people worldwide and is associated with increased susceptibility to respiratory infections, tuberculosis, and other infectious diseases. The LL-37 mechanism provides the molecular explanation: when vitamin D drops below the threshold needed to maintain adequate LL-37 expression, the body's first-line antimicrobial defense weakens.

Antimicrobial Research — Breadth and Synergy

LL-37's antimicrobial activity has been characterized against a wide range of pathogens. Key findings include:

• MRSA: Effective in a mouse wound infection model (PMC: 8532939), relevant given the crisis of antibiotic-resistant infections
• RSV: Inhibited respiratory syncytial virus in polarized airway epithelium models (PMID 26732674)
• Influenza A: Dose-dependent neutralization of multiple influenza A strains (PMID 23052388)
• Candida auris: Triggered oxidative stress and cell cycle arrest in this emerging multidrug-resistant fungal pathogen (PMID 35205958)
• Antibiotic synergy: 70% synergy rate with fluconazole, 100% with amphotericin B and caspofungin — suggesting LL-37 could enhance conventional antifungal therapy

Wound Healing — The Clinical Evidence Base

The venous leg ulcer RCT (PMID 25041740, 2014) remains the landmark clinical study: 34 patients, randomized, double-blind, placebo-controlled. Topical LL-37 at 0.5 mg/mL produced 68% mean ulcer area reduction — approximately sixfold faster healing than standard care. Higher doses (1.6 and 3.2 mg/mL) were less effective, demonstrating an inverted dose-response curve consistent with LL-37's concentration-dependent biology.

The diabetic foot ulcer RCT (PMID 37480520, 2023) confirmed topical efficacy in a different wound type and population.

Cancer Biology — The Defining Complication

The dual pro/anti-tumorigenic effects of LL-37 have been characterized across multiple tissue types (PMID 26395996, PMID 29843147). The pro-tumorigenic effects at physiologically relevant concentrations (~5 μg/mL) in ovarian, lung, breast, prostate cancers and melanoma represent a genuine safety signal that any immune health application must address.

The Innate Immune Defense System — Where Ll-37 Fits

To understand LL-37's role in immune health, it helps to understand the defense system it belongs to. The innate immune system is the body's first responder — it operates within minutes of pathogen contact, requires no prior exposure to the invader, and uses a repertoire of germline-encoded receptors (TLRs, NODs, RIG-I) to detect common microbial patterns.

Antimicrobial peptides (AMPs) are the innate immune system's chemical weapons. They are produced at every mucosal surface and released by immune cells at infection sites. Humans produce two major families: defensins (alpha and beta) and cathelicidins. LL-37 is the sole human cathelicidin — and it is the most functionally versatile AMP in the human arsenal.

What distinguishes LL-37 from other AMPs is its multifunctionality. Most defensins are primarily antimicrobial — they kill microbes. LL-37 kills microbes AND modulates the immune response AND promotes tissue repair AND signals to adaptive immune cells. It is not just a weapon; it is a coordinator. When LL-37 is released at an infection site, it simultaneously kills pathogens, recruits neutrophils and macrophages, shapes the developing immune response, and initiates the tissue repair process that will follow once the infection is controlled.

This is why LL-37 belongs in both Cluster B (Injury Recovery) and Cluster F (Immune Health). Wound healing is what LL-37 does after the immune defense phase succeeds. Immune defense is the primary function; tissue repair is the follow-through.

Claims vs. Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

The human evidence for LL-37 is limited to two small clinical trials, both using topical application for chronic wound healing:

Venous Leg Ulcer RCT (2014, PMID 25041740)

Design: Randomized, double-blind, placebo-controlled Phase I/II trial. 34 patients with hard-to-heal venous leg ulcers. Three-week open-label placebo run-in, followed by four-week treatment phase. Three dose arms (topical LL-37 at 0.5, 1.6, or 3.2 mg/mL) plus placebo, applied twice weekly.

Key findings: The 0.5 mg/mL group achieved 68% mean ulcer area reduction — approximately sixfold faster healing than the placebo group. Higher doses (1.6 and 3.2 mg/mL) were progressively less effective, with 3.2 mg/mL performing no better than placebo. This inverted dose-response curve is consistent with LL-37's concentration-dependent biology.

Limitations: Small sample (34 patients). Single center. Four-week treatment phase. First-in-human trial — primarily designed for safety, not definitive efficacy.

Diabetic Foot Ulcer RCT (2023, PMID 37480520)

Design: Randomized, double-blind, controlled trial. Diabetic foot ulcer patients with mild infection in Jakarta, Indonesia. Topical LL-37 cream versus placebo cream, twice weekly for four weeks.

Key findings: Enhanced wound healing rate and decreased inflammatory markers in the LL-37 group.

Limitations: Single center, specific population (diabetic patients with infected wounds in Southeast Asia). Small sample.

The Critical Route Gap

Both trials used topical application to chronic wounds. No published human data exists for subcutaneous, intramuscular, or intravenous LL-37. The community practice of injecting LL-37 for systemic immune modulation has zero clinical trial support. Topical delivery to a wound bed — where LL-37 acts locally on exposed tissue — is a fundamentally different pharmacological scenario than systemic injection, where the peptide must survive plasma degradation, distribute to target tissues, and achieve effective concentrations without triggering the cancer-promoting effects documented at ~5 μg/mL.

Safety, Risks, and Limitations

Topical Safety (Clinical Data)

Both RCTs reported no serious adverse events from topical LL-37 application. Mild local reactions at the application site were the only notable findings. No systemic toxicity was observed — but topical application delivers minimal systemic exposure.

The Cancer Promotion Risk

This is not a theoretical concern — it is demonstrated biology. LL-37 at approximately 5 μg/mL acts as a growth factor for ovarian, lung, breast, prostate cancers, malignant melanoma, and skin squamous cell carcinoma. The mechanism in ovarian cancer is well-characterized: LL-37 recruits multipotent mesenchymal stromal cells into the tumor stroma (PMID 19234121), creating a microenvironment that supports tumor growth.

The concentration at which these pro-tumorigenic effects occur (~5 μg/mL) overlaps with concentrations potentially achievable through exogenous administration. Anyone with an existing or occult malignancy in an LL-37-responsive tissue could theoretically accelerate tumor progression through exogenous LL-37. This is not a hypothetical scenario — it is a documented mechanism operating at clinically relevant concentrations.

Autoimmune Activation Risk

LL-37 is pathologically elevated in psoriasis and rosacea. In psoriasis, LL-37 forms complexes with self-DNA that activate plasmacytoid dendritic cells via TLR9, driving the autoimmune inflammatory cascade. In rosacea, excessive LL-37 production and aberrant processing by kallikrein 5 produces inflammatory fragments that cause the characteristic facial redness and papules.

This means LL-37 is not merely associated with these conditions — it is mechanistically involved in their pathology. Exogenous administration could theoretically worsen existing autoimmune skin conditions.

No Injectable Pharmacokinetic Data

No published data exists for the absorption, distribution, metabolism, and excretion of subcutaneously or intravenously administered LL-37 in humans. The peptide has a short plasma half-life due to enzymatic degradation. Whether injectable LL-37 achieves effective tissue concentrations, which tissues it reaches, and how long it persists are entirely unknown.

Legal and Regulatory Status

FDA Status: Not approved for any indication. No IND (Investigational New Drug application) has been filed for systemic use. Topical wound healing applications have been tested in Phase I/II clinical trials, but no FDA marketing authorization exists.

International: No regulatory approval in any jurisdiction for exogenous therapeutic use of LL-37.

WADA Status: Not specifically prohibited. LL-37 does not fall under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) or other currently prohibited categories. Athletes should verify current status annually through the WADA Prohibited List.

Compounding Access (US): LL-37 was placed in FDA Category 2 (do not compound) in 2023. The February 2026 HHS announcement indicated potential reclassification of some Category 2 peptides; LL-37's final disposition under this review is pending.

Research Protocols and Formulation Considerations

Clinical Trial Protocol (Topical)

The venous leg ulcer trial used LL-37 dissolved in solution at 0.5, 1.6, or 3.2 mg/mL, applied topically to chronic wounds twice weekly for four weeks. The diabetic foot ulcer trial used a cream formulation. Both protocols involved application to wound beds with existing tissue damage — not intact skin.

Reconstitution and Storage

• Form: Typically supplied as lyophilized powder (research grade)
• Reconstitution: Bacteriostatic water for injection
• Storage: 2–8°C (36–46°F) for reconstituted solution. Lyophilized powder more stable at -20°C
• Stability: LL-37 is relatively stable in wound fluid (~24 hours, PMID 21547341) but rapidly degraded in plasma
• For detailed reconstitution protocols, see Peptidings [Reconstitution Guide](/guides/reconstitution/)
• For storage best practices, see Peptidings [Storage Guide](/guides/storage/)

Dosing in Published Research

The following table summarizes dosing protocols for LL-37 as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.

Published Clinical Dosing (Topical Only)

Critical observation: The inverted dose-response curve (lower dose = better outcome) is consistent with LL-37's concentration-dependent biology and is a strong caution against the "more is better" assumption. For guidance on dosing principles, see Peptidings [More Is Not Always More Guide](/guides/more-is-more/).

Dosing in Self-Experimentation Communities

Community Protocols — Observation, Not Endorsement

The injectable community protocol has no published clinical basis. Community users report subjective immune benefits (reduced infection frequency, faster illness recovery), but these reports are anecdotal, uncontrolled, and subject to placebo effect and confirmation bias.

Combination Stacks

Research into LL-37 combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining LL-37 with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Compound	Type	Evidence Tier	Verdict	Mechanism	Primary Use Case	Human Data	FDA Status	WADA Status	Key Limitation
Thymosin Alpha-1	28-amino-acid peptide (thymus gland derivative)	Tier 1 — Approved Drug	Strong Foundation	Dendritic cell maturation + T-cell differentiation (Th1/Th17/Treg balance) + NK cell activation + TLR signaling enhancement; bidirectional immune modulation	Immune modulation; hepatitis B/C adjunct; vaccine enhancement; cancer immunotherapy adjunct	>11,000 in 30+ trials (Phase III TESTS sepsis N=3,600; HBV meta-analyses; adjuvant cancer trials)	Approved as Zadaxin in 35+ countries (NOT US/EU); US Category 2 compounding	Not specifically named; thymic peptides not prohibited	US access barrier (Category 2 compounding only); TESTS Phase III sepsis trial negative; evidence concentrated in Chinese/Italian institutions; geographic publication bias
LL-37	37-amino-acid peptide (human cathelicidin — only human member)	Tier 3 — Pilot / Limited Human Data	Eyes Open	Direct membrane disruption of pathogens + chemokine-like immune cell recruitment + TLR modulation + angiogenesis + wound healing via keratinocyte/fibroblast migration; vitamin D–regulated expression via CAMP gene	Innate immune defense; wound healing; antimicrobial; anti-biofilm	~74 across 2 small RCTs (venous leg ulcers N=34; diabetic foot ulcers N≈40) — all topical wound healing	Not approved	Not specifically prohibited	Cancer paradox (pro-tumorigenic at ~5 μg/mL in multiple cancers); route problem (injection destroys membrane-disruption advantage); two tiny topical RCTs only; no systemic human dosing data
KPV	Tripeptide (Lys-Pro-Val — C-terminal fragment of α-MSH)	Tier 4 — Preclinical Only	Thin Ice	NF-κB suppression at nanomolar concentrations + MAPK/ERK inhibition + PepT1-mediated intestinal uptake (transporter upregulated during IBD); does NOT bind melanocortin receptors	Anti-inflammatory; IBD/gut inflammation; immune modulation	None — zero human studies	Not approved	Not specifically prohibited	Zero human data; single research group dominance; nanoparticle formulation used in best studies not commercially available; raw peptide ≠ study formulation; route paradox (injection bypasses PepT1 gut transport)

Compound	Type	Primary Target	Half-Life	FDA Status	WADA Status	Evidence Tier	Primary Tissue Target	Route	Human Evidence Status	Key Differentiator
BPC-157	Synthetic pentadecapeptide (15 amino acids, derived from gastric protective protein BPC)	VEGF / Nitric oxide (proposed multi-target)	~2–6 hours	Not FDA-approved	Prohibited — S0 (Non-Approved Substances)	Tier 3 — Pilot / Limited Human Data	Musculoskeletal, tendon, ligament, GI tract, CNS	Subcutaneous injection + Oral (both routes studied)	3 published human pilot studies (~30 subjects combined); no RCTs	Broadest tissue tropism in cluster. Only injury-repair peptide with both oral and injectable evidence. Most evidence in rodent models
TB-500	Synthetic 4-amino-acid fragment (residues 17–23 of Thymosin Beta-4)	Actin binding (cell migration, angiogenesis)	~2–3 hours	Not FDA-approved	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 4 — Preclinical Only	Musculoskeletal (muscle, tendon, ligament), cardiac, neurological	Subcutaneous injection	Zero published human clinical trials; animal models and cell culture only	Smallest fragment studied; synthetic derivative of endogenous Thymosin Beta-4. Actin sequestration may drive cell migration
Thymosin Beta-4	Endogenous 43-amino-acid peptide (ubiquitous actin-sequestering protein)	Actin binding, cell migration, angiogenesis	~2–4 hours	Not FDA-approved	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 3 — Pilot / Limited Human Data	Broad: muscle, cardiac, neurological, immune, epithelial	Subcutaneous injection + Topical (cosmetics)	Few human studies; cardiac regeneration in early-stage human data; cosmetic formulations	Full-length parent peptide of TB-500. Endogenous compound; ubiquitous in mammalian tissues. More potent than TB-500 fragment in vitro
GHK-Cu	Synthetic tripeptide-copper complex (Gly-His-Lys chelated to Cu2+)	Collagen synthesis, wound healing, TGF-beta modulation	~2 hours topical; ~4–6 hours systemic (estimated)	Not FDA-approved (topical in cosmetics; injectable investigational)	Prohibited — S0 (injectable as growth factor analog); topical unregulated	Tier 5 — It's Complicated	Dermal (collagen, elastin remodeling); broad systemic effects proposed but unverified	Topical (cosmetics — extensive evidence) vs. Subcutaneous injection (preclinical only)	Topical: 30+ years cosmetic use data; Injectable: zero human trials	Route-dependent evidence: topical skin rejuvenation well-established, but injectable claims extrapolate from fundamentally different delivery
AHK-Cu	Synthetic copper tripeptide variant (Ala-His-Lys chelated to Cu2+)	Copper chelation, extracellular matrix remodeling, growth factor signaling	~2–4 hours (estimated)	Not FDA-approved	Not WADA-listed	Tier 4 — Preclinical Only	Dermal (hair follicle, scalp), cosmetic	Topical (cosmetics)	No human clinical trials; in vitro and cosmetic formulation data only	GHK-Cu structural analog with alanine substitution. Primarily studied for hair growth. Less evidence base than GHK-Cu
LL-37	Human cathelicidin antimicrobial peptide (37 amino acids)	Antimicrobial, wound healing, angiogenesis, vitamin D-regulated immune modulation	~2–4 hours	Not FDA-approved	Not WADA-listed	Tier 3 — Pilot / Limited Human Data	Skin, mucosal surfaces, immune system	Subcutaneous injection, Topical	Limited human data; antimicrobial efficacy well-characterized in vitro; wound healing in animal models	Endogenous host defense peptide. Dual role: direct antimicrobial activity + immune modulation. Vitamin D pathway regulates expression
KPV	Alpha-MSH C-terminal tripeptide (Lys-Pro-Val)	NF-kB inhibition, anti-inflammatory (no melanocortin receptor activation)	~1–2 hours (estimated)	Not FDA-approved	Not WADA-listed	Tier 4 — Preclinical Only	GI tract (colitis models), skin, immune system	Subcutaneous injection, Oral (investigational)	No published human clinical trials; animal models (colitis, dermatitis) only	Smallest anti-inflammatory peptide in cluster (3 amino acids). NF-kB pathway without melanocortin receptor binding. GI-focused research
VIP	Endogenous 28-amino-acid neuropeptide (vasoactive intestinal peptide)	VPAC1/VPAC2 receptor agonism; vasodilation, immunomodulation, bronchodilation	~1–2 minutes (extremely short)	Not FDA-approved (aviptadil in clinical trials)	Not WADA-listed	Tier 2 — Clinical Trials	Pulmonary, GI tract, immune system, neurological	Subcutaneous injection, IV infusion, Intranasal	Multiple Phase 2 trials (ARDS, pulmonary hypertension, sarcoidosis); aviptadil in FDA pipeline	Shortest half-life in cluster. CIRS protocol use. Aviptadil (synthetic VIP) is furthest along FDA pathway among non-approved compounds here
KGF / Palifermin	Recombinant keratinocyte growth factor (FGF-7)	FGFR2b receptor; keratinocyte proliferation, epithelial barrier repair	~3–5 hours	FDA-approved (Kepivance for oral mucositis)	Not WADA-listed	Tier 1 — Approved Drug	Epithelial surfaces (oral mucosa, GI tract, skin)	Intravenous injection (FDA-approved route)	FDA-approved for chemo-induced oral mucositis; multiple Phase 2/3 trials	Only FDA-approved compound in Cluster B. Specific to epithelial tissues. IV-only approved route limits off-label accessibility
Substance P	Endogenous 11-amino-acid tachykinin neuropeptide	NK1 receptor agonism; fibroblast migration, angiogenesis, immune activation	~1–2 minutes	Not FDA-approved	Not WADA-listed	Tier 3 — Pilot / Limited Human Data	Corneal epithelium, skin, nervous system	Topical (corneal), Subcutaneous injection	Human data primarily in corneal wound healing; limited systemic human studies	Endogenous pain signaling peptide repurposed for tissue repair. Strongest human evidence in corneal healing. Dual role: nociception + repair
PRP	Autologous platelet-rich plasma (concentrated growth factor preparation)	PDGF, VEGF, TGF-beta release via platelet degranulation	N/A (not a single molecule)	FDA-cleared devices (not drug-approved)	Prohibited — M1 (Manipulation of Blood and Blood Components)	Tier 2 — Clinical Trials	Musculoskeletal (tendon, cartilage, bone), dermal, hair	Injection (local to injury site)	Hundreds of RCTs across orthopedic, dermatologic, and dental applications	Non-peptide. Autologous preparation — no synthetic manufacturing. Largest clinical evidence base in cluster but high study heterogeneity
ARA-290	Synthetic 11-amino-acid peptide (cibinetide; EPO-derived tissue-protective peptide)	Innate Repair Receptor (EPOR/CD131 heterodimer) selective agonist	~2–4 hours	Not FDA-approved (Phase 2b completed)	Not WADA-listed	Tier 2 — Clinical Trials	Peripheral nerves, retina, cardiac, immune system	Subcutaneous injection (1–8 mg daily in trials); IV infusion (early trials)	Phase 2b complete (sarcoidosis SFN — DOSARA trial); Phase 2 (diabetic neuropathy, diabetic macular edema)	EPO-derived but does NOT bind classical EPO receptor. No erythropoietic activity. Tissue protection without blood doping risk. Furthest clinical development for neuropathy

Compound	Type	Evidence Tier	Verdict	Mechanism	Primary Use Case	Human Data	FDA Status	WADA Status	Key Limitation
Thymosin Alpha-1	28-amino-acid peptide (thymus gland derivative)	Tier 1 — Approved Drug	Strong Foundation	Dendritic cell maturation + T-cell differentiation (Th1/Th17/Treg balance) + NK cell activation + TLR signaling enhancement; bidirectional immune modulation	Immune modulation; hepatitis B/C adjunct; vaccine enhancement; cancer immunotherapy adjunct	>11,000 in 30+ trials (Phase III TESTS sepsis N=3,600; HBV meta-analyses; adjuvant cancer trials)	Approved as Zadaxin in 35+ countries (NOT US/EU); US Category 2 compounding	Not specifically named; thymic peptides not prohibited	US access barrier (Category 2 compounding only); TESTS Phase III sepsis trial negative; evidence concentrated in Chinese/Italian institutions; geographic publication bias
LL-37	37-amino-acid peptide (human cathelicidin — only human member)	Tier 3 — Pilot / Limited Human Data	Eyes Open	Direct membrane disruption of pathogens + chemokine-like immune cell recruitment + TLR modulation + angiogenesis + wound healing via keratinocyte/fibroblast migration; vitamin D–regulated expression via CAMP gene	Innate immune defense; wound healing; antimicrobial; anti-biofilm	~74 across 2 small RCTs (venous leg ulcers N=34; diabetic foot ulcers N≈40) — all topical wound healing	Not approved	Not specifically prohibited	Cancer paradox (pro-tumorigenic at ~5 μg/mL in multiple cancers); route problem (injection destroys membrane-disruption advantage); two tiny topical RCTs only; no systemic human dosing data
KPV	Tripeptide (Lys-Pro-Val — C-terminal fragment of α-MSH)	Tier 4 — Preclinical Only	Thin Ice	NF-κB suppression at nanomolar concentrations + MAPK/ERK inhibition + PepT1-mediated intestinal uptake (transporter upregulated during IBD); does NOT bind melanocortin receptors	Anti-inflammatory; IBD/gut inflammation; immune modulation	None — zero human studies	Not approved	Not specifically prohibited	Zero human data; single research group dominance; nanoparticle formulation used in best studies not commercially available; raw peptide ≠ study formulation; route paradox (injection bypasses PepT1 gut transport)

Related Compounds: How LL-37 Compares

LL-37 belongs to a broader family of compounds being investigated for similar applications. The table below compares key characteristics across related compounds in the Immune Health cluster.

Mechanistic overlap does not imply equivalent evidence. Each compound has a distinct research profile, regulatory status, and level of clinical validation.

Compound	Type	Evidence Tier	Verdict	Mechanism	Primary Use Case	Human Data	FDA Status	WADA Status	Key Limitation
Thymosin Alpha-1	28-amino-acid peptide (thymus gland derivative)	Tier 1 — Approved Drug	Strong Foundation	Dendritic cell maturation + T-cell differentiation (Th1/Th17/Treg balance) + NK cell activation + TLR signaling enhancement; bidirectional immune modulation	Immune modulation; hepatitis B/C adjunct; vaccine enhancement; cancer immunotherapy adjunct	>11,000 in 30+ trials (Phase III TESTS sepsis N=3,600; HBV meta-analyses; adjuvant cancer trials)	Approved as Zadaxin in 35+ countries (NOT US/EU); US Category 2 compounding	Not specifically named; thymic peptides not prohibited	US access barrier (Category 2 compounding only); TESTS Phase III sepsis trial negative; evidence concentrated in Chinese/Italian institutions; geographic publication bias
LL-37	37-amino-acid peptide (human cathelicidin — only human member)	Tier 3 — Pilot / Limited Human Data	Eyes Open	Direct membrane disruption of pathogens + chemokine-like immune cell recruitment + TLR modulation + angiogenesis + wound healing via keratinocyte/fibroblast migration; vitamin D–regulated expression via CAMP gene	Innate immune defense; wound healing; antimicrobial; anti-biofilm	~74 across 2 small RCTs (venous leg ulcers N=34; diabetic foot ulcers N≈40) — all topical wound healing	Not approved	Not specifically prohibited	Cancer paradox (pro-tumorigenic at ~5 μg/mL in multiple cancers); route problem (injection destroys membrane-disruption advantage); two tiny topical RCTs only; no systemic human dosing data
KPV	Tripeptide (Lys-Pro-Val — C-terminal fragment of α-MSH)	Tier 4 — Preclinical Only	Thin Ice	NF-κB suppression at nanomolar concentrations + MAPK/ERK inhibition + PepT1-mediated intestinal uptake (transporter upregulated during IBD); does NOT bind melanocortin receptors	Anti-inflammatory; IBD/gut inflammation; immune modulation	None — zero human studies	Not approved	Not specifically prohibited	Zero human data; single research group dominance; nanoparticle formulation used in best studies not commercially available; raw peptide ≠ study formulation; route paradox (injection bypasses PepT1 gut transport)

Frequently Asked Questions

Summary of Key Findings

LL-37 is the sole human cathelicidin — your body's most versatile innate immune defense molecule. It kills bacteria, viruses, and fungi directly, recruits and directs immune cells, and promotes wound healing. The vitamin D–LL-37 axis is one of the most important molecular connections in innate immunology.

1. Vitamin D controls LL-37 production. This is the most actionable finding: adequate vitamin D supplementation supports endogenous LL-37 expression through a well-characterized molecular mechanism. For most people, optimizing vitamin D is a safer approach to LL-37 support than exogenous administration.

2. Antimicrobial breadth is real. LL-37's activity against bacteria (including MRSA), viruses (RSV, influenza), and fungi (Candida auris) is well-documented in vitro and in animal models. Antibiotic synergy is demonstrated.

3. Human evidence is limited to topical wound healing. Two small RCTs showed efficacy for chronic wound healing with topical application. No injectable human data exists.

4. The cancer paradox is not optional reading. Pro-tumorigenic effects at ~5 μg/mL in multiple cancer types are documented. This risk applies to any exogenous LL-37 administration and cannot be dismissed.

5. Immune modulation goes beyond killing. LL-37 recruits immune cells, shapes inflammatory responses, neutralizes endotoxin, and bridges innate and adaptive immunity. It is a coordinator, not just a weapon.

6. Route matters profoundly. Topical wound data does not validate injectable immune claims. The community practice of injecting LL-37 for systemic immune support operates without any clinical trial foundation.

7. More is not better. The inverted dose-response in the venous leg ulcer trial — where the lowest dose was most effective — is consistent with LL-37's concentration-dependent biology and the cancer promotion concern.

Verdict Recapitulation

LL-37 earns Tier 3 on the strength of two small but real clinical trials, both topical. The Eyes Open verdict reflects the gap between LL-37's fascinating biology and the safety unknowns of exogenous systemic administration — particularly the documented cancer-promoting effects at achievable concentrations. The vitamin D connection provides an evidence-backed alternative pathway to LL-37 support that does not carry the same risks.

For readers considering LL-37, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source LL-37

Further Reading and Resources

If you want to go deeper on LL-37, the evidence landscape for immune health peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Immune Health Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: LL-37 — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Heilborn JD, et al. (2014). "Treatment of hard-to-heal venous leg ulcers with LL-37: A randomized, double-blind, placebo-controlled Phase I/II clinical trial." Wound Repair and Regeneration. PMID 25041740
2. Riwanto M, et al. (2023). "Topical LL-37 for diabetic foot ulcers with mild infection: A randomized controlled trial." Journal of Wound Care. PMID 37480520
3. Vandamme D, et al. (2012). "A comprehensive summary of LL-37, the factotum human cathelicidin peptide." Cellular Immunology. PMID 23246832
4. Coffelt SB, et al. (2009). "The pro-tumorigenic role of LL-37 in ovarian cancer." Molecular Cancer Research. PMID 19234121
5. Ren SX, et al. (2022). "LL-37 inhibits pancreatic cancer growth by suppressing autophagy and reprogramming tumor immune microenvironment." PMC: 9355328
6. Wu WK, et al. (2015). "The dual roles of LL-37 in cancer." Molecular Cancer. PMID 26395996
7. Chen X, et al. (2018). "The roles of cathelicidin LL-37 in cancer." Frontiers in Oncology. PMID 29843147
8. Liu PT, et al. (2006). "Toll-like receptor triggering of a vitamin D–mediated human antimicrobial response." Science. PMID 16497887
9. Sørensen OE, et al. (2011). "LL-37 stability in wound fluid." PMID 21547341
10. Turner J, et al. (2021). "LL-37 in a methicillin-resistant Staphylococcus aureus wound model." PMC: 8532939
11. Currie SM, et al. (2016). "LL-37 inhibits RSV infection in polarized airway epithelium." PMID 26732674
12. Tripathi S, et al. (2012). "LL-37 dose-dependent neutralization of influenza A." PMID 23052388
13. Shurko JF, et al. (2022). "LL-37 triggers oxidative stress and cell cycle arrest in Candida auris." PMID 35205958
14. von Haussen J, et al. (2011). "LL-37 as a growth factor for malignant melanoma." PMID 20977442

---